Searchable abstracts of presentations at key conferences in endocrinology

ea0032p753 | Obesity | ECE2013

Chronic central administration of amylin decreases fat mass but does not modify body weight

Touceda David Gonzalez , Pico Amparo Romero , Piedra Monica Imbernon , Couto Begona Porteiro , Tarrio Daniel Beiroa , Lopez Miguel , Nogueiras Ruben , Dieguez Carlos

Aims (objectives): Energy intake and expenditure are regulated by different signals. One of the molecules implicated is islet amyloid polypeptide (IAPP or amylin), one of the major secretory products of β-cells of the pancreatic islets of Langerhans. It is a peptide that inhibits insulin and glucagon secretion, and can also act through the brain decreasing food intake and inhibiting gastric emptying. In this study, we investigated the potential effects of the chronic cent...

ea0056gp156 | Obesity | ECE2018

Pharmacological stimulation of p53 with low-dose doxorubicin ameliorates diet-induced nonalcoholic steatosis and steatohepatitis

Rellan Maria Jesus Gonzalez , Couto Begona Porteiro , Fondevila Marcos Fernandez , Buque Xabier , Fernandez Uxia , Mora Alfonso , Beiroa Daniel , Lopez Miguel , Sabioc Guadalupe , Dieguez Carlos , Aspichueta Patricia , Nogueiras Ruben

Introduction: p53 is a transcription factor involved in many biological functions such as stress, ageing, and metabolism. Although there is a large body of evidence showing that p53 promotes fatty acid catabolism while it inhibits anabolism through the regulation of gene expression, the possible contribution of p53 to the pathogenesis of nonalcoholic fatty liver disease (NAFLD) remains to be elucidated. Also, the anthracycline doxorubicin is an important chemotherapeutic agent...